Company Filing History:
4 out of 113 
3 out of 1,309 
2 out of 1,343 
Years Active: 1998-2020
Title: Arthur Kunz: Innovator in Biologically Active Molecule Conjugates
Introduction
Arthur Kunz is a notable inventor based in New City, NY (US). He has made significant contributions to the field of biologically active molecule conjugates, holding a total of 10 patents. His work focuses on the development of innovative therapeutic methods and reagents that have the potential to impact medical treatments.
Latest Patents
Kunz's latest patents include groundbreaking work on biologically active molecule conjugates, reagents, and methods of manufacture, as well as their therapeutic uses. The first patent discusses conjugates that comprise biologically active molecules linked to a multimeric antigen-binding compound or a multimeric immunoglobulin via a linker. This disclosure also provides methods for manufacturing these conjugates and the linkers, along with compositions that include the conjugates. Furthermore, it outlines methods for modifying abnormal cell growth and treatment methods using these conjugates or compositions. His second patent focuses on antibody-drug conjugates, detailing their preparation and therapeutic applications, which further emphasizes his expertise in this innovative area.
Career Highlights
Throughout his career, Arthur Kunz has worked with prominent companies such as Wyeth Holdings Corporation and Wyeth. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in therapeutic technologies.
Collaborations
Kunz has collaborated with notable professionals in his field, including Nitin Krishnaji Damle and Justin Keith Moran. These collaborations have likely enriched his research and development efforts, leading to innovative solutions in the medical field.
Conclusion
Arthur Kunz is a distinguished inventor whose work in biologically active molecule conjugates has the potential to revolutionize therapeutic methods. His contributions, backed by a solid patent portfolio, highlight his commitment to advancing medical science.